סימבקסון 40

Land: Israël

Taal: Hebreeuws

Bron: Ministry of Health

Koop het nu

Bijsluiter Bijsluiter (PIL)
06-07-2021

Werkstoffen:

SIMVASTATIN

Beschikbaar vanaf:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC-code:

C10AA01

farmaceutische vorm:

קפליות

Samenstelling:

SIMVASTATIN 40 MG

Toedieningsweg:

פומי

Prescription-type:

מרשם נדרש

Geproduceerd door:

DEXCEL LTD, ISRAEL

Therapeutische categorie:

SIMVASTATIN

Therapeutisch gebied:

SIMVASTATIN

therapeutische indicaties:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Product samenvatting:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Autorisatie datum:

2020-04-30

Documenten in andere talen

Bijsluiter Bijsluiter Engels 20-01-2021
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Engels 18-08-2016
Bijsluiter Bijsluiter Arabisch 20-01-2021

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten